Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2C | P18825 | 1/20 | 0.61 |
| ▸ | HTR2A | P28223 | 2/20 | 0.52 |
| ▸ | HTR1A | P08908 | 1/20 | 0.52 |
| ▸ | HTR2C | P28335 | 1/20 | 0.52 |
| ▸ | HTR7 | P34969 | 1/20 | 0.52 |
| ▸ | DRD3 | P35462 | 1/20 | 0.52 |
| ▸ | HTR6 | P50406 | 1/20 | 0.52 |
| ▸ | HTR1D | P28221 | 1/20 | 0.50 |
| ▸ | HTR1B | P28222 | 1/20 | 0.50 |
| ▸ | HTR3A | P46098 | 1/20 | 0.50 |
| ▸ | AGXT | P21549 | 1/20 | 0.50 |
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.48 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | CASP7 | P55210 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.46 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.46 |
| ▸ | CDK2 | P24941 | 3/20 | 0.46 |
| ▸ | CDK9 | P50750 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18801748 | 0.85 | PRMT6 (0.56) | ADRA2CAGXTMAPTCCNT1CCNA2 | |
| SCHEMBL113800 | 0.84 | PRMT6 (0.58) | AGXTMAPTCCNT1CCNA2CDK2 | |
| SCHEMBL2376465 | 0.81 | CHRNA7 (0.59) | MAPTKDM4EGAA | |
| SCHEMBL18946090 | 0.81 | FAAH (0.46) | ADRA2CHTR2AHTR1AHTR2CHTR7 | |
| SCHEMBL3433102 | 0.81 | ADRA2C (0.56) | ADRA2CHTR2AHTR1AHTR2CHTR7 | |
| SCHEMBL25156906 | 0.81 | ADRA2C (0.56) | ADRA2CHTR2AHTR1AHTR2CHTR7 | |
| SCHEMBL13996557 | 0.81 | ADRA2C (0.56) | ADRA2CHTR2AHTR1AHTR2CHTR7 | |
| SCHEMBL13994004 | 0.81 | ADRA2C (0.56) | ADRA2CHTR2AHTR1AHTR2CHTR7 | |
| SCHEMBL3230491 | 0.81 | DRD2 (0.51) | HTR1AHTR7MAPTJAK2JAK3 | |
| SCHEMBL6264215 | 0.81 | ADRB1 (0.62) | HTR2AHTR1AHTR2CHTR7DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2050749-B1 | PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2017-11-22 | — | — | EP | claimed |
| WO-2021145729-A1 | NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2021-07-22 | — | — | WO | disclosed |
| EP-3048106-B1 | THIENOPYRIMIDINE AS INHIBITORS OF ATYPICAL PROTEIN KINASE C | CANCER RESEARCH TECH LTD (GB) | 2019-11-06 | — | — | EP | disclosed |
| EP-2050749-B1 | PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2017-11-22 | — | — | EP | disclosed |
| EP-2050749-B1 | PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2017-11-22 | — | — | EP | disclosed |
| CN-104822267-A | INHIBITORS OF HEPATITIS B VIRUS CONVALENTLY CLOSED CIRCULAR DNA FORMATION AND THEIR METHOD OF USE | BARUCH S BLUMBERG INST | 2015-08-05 | — | — | CN | disclosed |
| CN-101501035-B | Pyrimidine derivatives as PI3K inhibitors and uses thereof | CHUGAI PHARMACEUTICAL CO LTD | 2013-01-23 | — | — | CN | disclosed |
| US-8022205-B2 | Pyrimidine derivatives as PI3K inhibitor and use thereof | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-09-20 | — | — | US | disclosed |
| US-8022205-B2 | Pyrimidine derivatives as PI3K inhibitor and use thereof | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-09-20 | — | — | US | disclosed |
| US-8022205-B2 | Pyrimidine derivatives as PI3K inhibitor and use thereof | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-09-20 | — | — | US | disclosed |
| US-20100069629-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-03-18 | — | — | US | disclosed |
| US-20100069629-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-03-18 | — | — | US | disclosed |
| CN-101501035-A | Pyrimidine derivatives as P13K inhibitors and uses thereof | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2009-08-05 | — | — | CN | disclosed |
| EP-2050749-A1 | PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-04-22 | — | — | EP | disclosed |
| EP-2050749-A1 | PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069629-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF | PIK3CA, AKT3, AKT1 | ADRA2C 4452/4885HTR2A 3778/4885HTR1A 2914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.